CN103172627A - 杂环嘧啶苯或吡啶苯类化合物及其应用 - Google Patents
杂环嘧啶苯或吡啶苯类化合物及其应用 Download PDFInfo
- Publication number
- CN103172627A CN103172627A CN2011104406519A CN201110440651A CN103172627A CN 103172627 A CN103172627 A CN 103172627A CN 2011104406519 A CN2011104406519 A CN 2011104406519A CN 201110440651 A CN201110440651 A CN 201110440651A CN 103172627 A CN103172627 A CN 103172627A
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- group
- cycloalkyl
- alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 14
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 3
- -1 quinoline compound Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 23
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 230000008482 dysregulation Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- CRLNSROCLKFIOK-UHFFFAOYSA-N benzene;pyrimidine Chemical compound C1=CC=CC=C1.C1=CN=CN=C1 CRLNSROCLKFIOK-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract description 12
- 229940080856 gleevec Drugs 0.000 abstract description 12
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 58
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 238000010189 synthetic method Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 10
- 0 Cc1nc(CCc2cc(*)c(*)c(*)c2)cc(Nc2ncc(C(CI)c3c(*)cc(*)cc3*)[s]2)n1 Chemical compound Cc1nc(CCc2cc(*)c(*)c(*)c2)cc(Nc2ncc(C(CI)c3c(*)cc(*)cc3*)[s]2)n1 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002448 dasatinib Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- WFNLHDJJZSJARK-UHFFFAOYSA-N 2-chloro-6-methylaniline Chemical compound CC1=CC=CC(Cl)=C1N WFNLHDJJZSJARK-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- WDTVJRYCMIZPMX-UHFFFAOYSA-N 4-chloro-2-methylpyrimidine Chemical class CC1=NC=CC(Cl)=N1 WDTVJRYCMIZPMX-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
- WHUKQYXSOIBAIE-UHFFFAOYSA-N Cc(cccc1Br)c1NC(c1cnc(Nc2cc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)nc(C)n2)[s]1)=O Chemical compound Cc(cccc1Br)c1NC(c1cnc(Nc2cc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)nc(C)n2)[s]1)=O WHUKQYXSOIBAIE-UHFFFAOYSA-N 0.000 description 1
- IEHXBXBKGHDMFD-UHFFFAOYSA-N Cc(cccc1Br)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O Chemical compound Cc(cccc1Br)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O IEHXBXBKGHDMFD-UHFFFAOYSA-N 0.000 description 1
- NEOKFURHKVEJRV-UHFFFAOYSA-N Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O Chemical compound Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O NEOKFURHKVEJRV-UHFFFAOYSA-N 0.000 description 1
- ZQIOQHNGPYZJEB-UHFFFAOYSA-N Cc(cccc1F)c1NC(c1cnc(Nc2nc(C)cc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O Chemical compound Cc(cccc1F)c1NC(c1cnc(Nc2nc(C)cc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O ZQIOQHNGPYZJEB-UHFFFAOYSA-N 0.000 description 1
- AHSQSKIQRFQZHR-UHFFFAOYSA-N Cc(cccc1F)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O Chemical compound Cc(cccc1F)c1NC(c1cnc(Nc2nc(C)nc(Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)c2)[nH]1)=O AHSQSKIQRFQZHR-UHFFFAOYSA-N 0.000 description 1
- BRBUBVKGJRPRRD-UHFFFAOYSA-N Cc1cc(N)nc(C)c1 Chemical compound Cc1cc(N)nc(C)c1 BRBUBVKGJRPRRD-UHFFFAOYSA-N 0.000 description 1
- BJJDXAFKCKSLTE-UHFFFAOYSA-N Cc1cc(N)nc(C)n1 Chemical compound Cc1cc(N)nc(C)n1 BJJDXAFKCKSLTE-UHFFFAOYSA-N 0.000 description 1
- FOVGTACENAPYKQ-UHFFFAOYSA-N Cc1cnc(Nc2nc(C)cc(C)c2)[nH]1 Chemical compound Cc1cnc(Nc2nc(C)cc(C)c2)[nH]1 FOVGTACENAPYKQ-UHFFFAOYSA-N 0.000 description 1
- QLAXXUAHXVPEJG-UHFFFAOYSA-N Cc1cnc(Nc2nc(C)nc(C)c2)[nH]1 Chemical compound Cc1cnc(Nc2nc(C)nc(C)c2)[nH]1 QLAXXUAHXVPEJG-UHFFFAOYSA-N 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AITBHTAFQQYBHP-UHFFFAOYSA-N benzene;pyridine Chemical class C1=CC=CC=C1.C1=CC=NC=C1 AITBHTAFQQYBHP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- SRTKIHVQZYXHHJ-UHFFFAOYSA-N n-methyl-3-(trifluoromethyl)aniline Chemical compound CNC1=CC=CC(C(F)(F)F)=C1 SRTKIHVQZYXHHJ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110440651.9A CN103172627B (zh) | 2011-12-26 | 2011-12-26 | 杂环嘧啶苯或吡啶苯类化合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110440651.9A CN103172627B (zh) | 2011-12-26 | 2011-12-26 | 杂环嘧啶苯或吡啶苯类化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103172627A true CN103172627A (zh) | 2013-06-26 |
CN103172627B CN103172627B (zh) | 2015-11-18 |
Family
ID=48632880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110440651.9A Expired - Fee Related CN103172627B (zh) | 2011-12-26 | 2011-12-26 | 杂环嘧啶苯或吡啶苯类化合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103172627B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006099474A1 (en) * | 2005-03-15 | 2006-09-21 | Bristol-Myers Squibb Company | 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites |
WO2008150446A1 (en) * | 2007-05-30 | 2008-12-11 | Congxin Liang | Inhibitors of protein kinases |
CN101973989A (zh) * | 2010-05-17 | 2011-02-16 | 苏州波锐生物医药科技有限公司 | 一种噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途 |
-
2011
- 2011-12-26 CN CN201110440651.9A patent/CN103172627B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006099474A1 (en) * | 2005-03-15 | 2006-09-21 | Bristol-Myers Squibb Company | 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites |
WO2008150446A1 (en) * | 2007-05-30 | 2008-12-11 | Congxin Liang | Inhibitors of protein kinases |
CN101973989A (zh) * | 2010-05-17 | 2011-02-16 | 苏州波锐生物医药科技有限公司 | 一种噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN103172627B (zh) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10350210B2 (en) | EGFR and ALK dual inhibitor | |
RU2528408C2 (ru) | Сп0соб получения соединений дигидроинденамида, фармацевтические композии, содержащие данные соединение и их применение в качестве ингибитора протеинкиназы | |
CN103003278B (zh) | 芳胺基嘌呤衍生物及其制备方法和在医药上的用途 | |
WO2014025128A1 (ko) | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
MX2007008372A (es) | Ureas disustituidas como inhibidores de cinasa. | |
KR20190140966A (ko) | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 | |
AU2018286221A1 (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
US20150210702A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
CN107245075A (zh) | 2,4,6‑三取代吡啶并[3,4‑d]嘧啶类化合物及其盐和应用 | |
CN112300082B (zh) | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 | |
CN104230954A (zh) | 2,4-二氨基嘧啶类化合物及其医药用途 | |
Devegowda et al. | Synthesis, characterization of 4-anilino-6, 7-dimethoxy quinazoline derivatives as potential anti-angiogenic agents | |
WO2021129561A1 (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
CN1854130B (zh) | 喹唑啉衍生物、及其制法和药物组合物与用途 | |
CN107383019A (zh) | 吡唑并[4,3‑h]喹唑啉类化合物及其用途 | |
CN107001317B (zh) | 高选择性取代嘧啶类pi3k抑制剂 | |
CN103172627B (zh) | 杂环嘧啶苯或吡啶苯类化合物及其应用 | |
CN111718325A (zh) | 一种2,4,5-取代嘧啶类化合物及其制备方法和应用 | |
CN106866642B (zh) | 含芳基酰腙结构的喹唑啉类化合物及其应用 | |
CN115322158A (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
CN105541792B (zh) | 多环类pi3k抑制剂 | |
CN110724137B (zh) | 一种噻吩类衍生物及其制备方法与应用 | |
CN113072550B (zh) | 一种高选择性成纤维细胞生长因子受体抑制剂和应用 | |
CN109438279B (zh) | 一种克服egfr耐药突变的小分子化合物及其制备方法和用途 | |
CA3184218A1 (en) | Aryl phosphorus oxide compounds and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address before: No. 28, Heng Jing Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee before: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address before: 201, room 01, building 108, East 210000, Gan Hua Street, Yao Road, Qixia District, Jiangsu, Nanjing Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 |
|
CF01 | Termination of patent right due to non-payment of annual fee |